Healthcare

Whirly lollipop on orange background.

Celladon IPO back from the dead

Celladon (CLDN) is a clinical-stage biotechnology company that postponed their IPO at when it was being marketed at much higher prices. They’ve jumped back into the market with a much-reduced proposed price of $8/share and some interest from insiders in buying shares on the IPO. The deal is now $40M in value and the pro-forma…

Keep Reading
Whirly lollipop on orange background.

Dicerna Pharma (DRNA) promises targeted drug delivery and a small float

Dicerna Pharma (DCRN) is scheduled to price tonight. The calendar is full of biotech companies but demand for this one is good due in no small part to the willingness of existing shareholders to buy a big part of the deal. Dicerna is pre-clinical so sales are a long way off but the company does…

Keep Reading
Whirly lollipop on orange background.

Care.com IPO offers High Return with High Risk

Care.com (CRCM) is on the road now with a $90M IPO led by Morgan Stanley. There are about 6M shares being offered with a mid-point of $15. The deal is currently scheduled for Friday, January 24th. [Here is a link to the CRCM IPO Roadshow Slide Deck for reference.] Care.com is positioning themselves as the…

Keep Reading
Whirly lollipop on orange background.

GlycoMimetics Tries Again with Lower Price and More Shares

GlycoMimetics (GLYC) paused their deal late last year when the terms were $14 to $16/share with 4M shares offered. This week they are back with a short marketing duration and a lower price of $8/share and 5.7M shares offered plus the typical 15% over allotment. Insiders including Pfizer (PFE) have agreed to buy $14M of…

Keep Reading
Whirly lollipop on orange background.

Biotech IPO Update for May/June

Biotech IPOs are definitely back. In addition to recent pricings we have 4 more deals in active marketing and there were 9 new filings in the last 30 days. We’ve added the recent crop of companies to the roadshow archive. Their descriptions and links are below. Adding up the market capitalizations of just these deals…

Keep Reading
Whirly lollipop on orange background.

GlobeImmune offers little promise for IPO investors.

GlobeImmune (GBIM) is scheduled to price their IPO this week. Wells Fargo and Piper are leading the underwriting group for this $60M IPO (5M shares with a $12 mid-point.) This would put a valuation of $206M on the 36-person company. On the positive side at least one pharma partner (Celgene) is planning to purchase shares…

Keep Reading
Whirly lollipop on orange background.

Pre-IPO Interview with WhiteGlove CEO

We published an interview today with Robert Fabbio, Founder & CEO of WhiteGlove House Call Health, Inc., a company that has filed an S-1 in preparation for an IPO. Please see important disclaimers at the end of the report. The document (PDF) is available via this link: R2 Pre IPO Interview White Glove Final May…

Keep Reading
Whirly lollipop on orange background.

DynaVox Post-IPO Notes

We’ve had DynaVox on our radar screen for some time as makes use of a RealVR technology (speech) to give people with disabilities a way to speak and interact, which fits in with our HealthTech angle. Today the shares were off over 20% to under $12 after their fiscal Q4 report made investors view the…

Keep Reading
Whirly lollipop on orange background.

More IPO Presentations: SurgiVision and Envestnet

SurgiVision is a company we are following because it crosses two major themes we like, health technology and real VR. However, the company is more development stage than we expected. The ability to do surgery based on vision from MRI does seem inevitable, and their technology appears ready, but the pace of adoption is hard…

Keep Reading